Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
$7.89
$7.89
$1.06
$8.58
$651.87M1.28183,275 shsN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
$0.88
+6.0%
$1.00
$1.78
$40.66
$26.44M1.4620,672 shs154,914 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$164.26
+2.6%
$165.75
$93.95
$189.97
$4.57B0.9233,447 shs205,660 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$7.38
-0.8%
$6.47
$1.61
$10.24
$849.49M3.46231,570 shs95,482 shs
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
$9.21
-4.2%
$10.37
$7.51
$21.70
$237.62M1.42223,859 shs273,806 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
0.00%0.00%0.00%0.00%0.00%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
+5.66%+3.19%-10.97%-27.52%-42.30%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+2.63%+0.88%+1.96%-3.85%+32.25%
Mesoblast Limited stock logo
MESO
Mesoblast
-0.81%-9.67%-1.60%+258.25%+1.65%
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-4.16%+13.70%+5.26%-46.17%-32.63%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
N/AN/AN/AN/AN/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.7949 of 5 stars
1.51.00.04.72.13.33.1
Mesoblast Limited stock logo
MESO
Mesoblast
2.2013 of 5 stars
3.15.00.00.02.60.80.6
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
1.6475 of 5 stars
3.31.00.00.03.41.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
N/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$177.638.14% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
2.17
Hold$13.6785.19% Upside
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
2.60
Moderate Buy$24.60167.10% Upside

Current Analyst Ratings

Latest AVMXY, MESO, CRTX, RCEL, and KRYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$21.00 ➝ $9.00
5/14/2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$22.00 ➝ $21.00
5/6/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00
4/22/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00
4/16/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$178.00 ➝ $204.00
4/11/2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 6/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
$5.51M118.31N/AN/A$0.26 per share30.35
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A$3.97 per shareN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$50.70M92.53N/AN/A$27.60 per share5.95
Mesoblast Limited stock logo
MESO
Mesoblast
$7.50M112.35N/AN/A$6.16 per share1.20
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
$50.70M4.69N/AN/A$1.92 per share4.80

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
-$24.75M-$0.39N/AN/AN/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$10.93M$1.8787.8437.94N/AN/A-5.74%-5.45%8/5/2024 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$81.89M-$1.12N/AN/AN/AN/AN/AN/A6/6/2024 (Estimated)
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-$35.38M-$1.76N/AN/AN/A-88.41%-84.07%-47.63%8/8/2024 (Estimated)

Latest AVMXY, MESO, CRTX, RCEL, and KRYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024Q1 2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-$0.26-$0.73-$0.47-$0.73$11.08 million$11.10 million    
5/6/2024Q1 2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$0.20$0.03-$0.17$0.03$47.37 million$45.25 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
N/AN/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
N/A
5.50
5.33
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/A
9.92
9.92
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
12.65
12.42
Mesoblast Limited stock logo
MESO
Mesoblast
0.21
2.71
N/A
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
1.27
7.25
6.64

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
0.01%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
63.18%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
27.66%

Insider Ownership

CompanyInsider Ownership
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
N/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
27.90%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
14.10%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
1.82%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
5582.62 millionN/ANot Optionable
Cortexyme, Inc. stock logo
CRTX
Cortexyme
5530.15 million21.74 millionNot Optionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
22928.56 million24.53 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
83114.18 million92.71 millionOptionable
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
20725.80 million25.33 millionOptionable

CRTX, RCEL, AVMXY, KRYS, and MESO Headlines

Recent News About These Companies

AVITA Medical Announces FDA Approval of RECELL GO
Avita Medical (NASDAQ: RCEL) - Share Price and Research
AVITA Medical to Host Investor Webinar Briefing
Piper Sandler Reaffirms Their Hold Rating on Avita Medical (RCEL)
Analyst Ratings For AVITA Medical
AVITA Medical Inc RCEL
Avita Medical Ltd (RCEL)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AVITA MED LTD/S logo

AVITA MED LTD/S

OTCMKTS:AVMXY
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.
Cortexyme logo

Cortexyme

NASDAQ:CRTX
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Krystal Biotech logo

Krystal Biotech

NASDAQ:KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Mesoblast logo

Mesoblast

NASDAQ:MESO
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
AVITA Medical logo

AVITA Medical

NASDAQ:RCEL
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.